MedTrace Logo

Rho Kinase (ROCK) Inhibition in Carotid Atherosclerosis

NCT00670202 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2017-03-29

Study results available
· View outcomes & findings →

Summary

To evaluate the causal relationship between Rho/Rho kinase overactivity and mechanisms of vascular dysfunction in patients with atherosclerosis.

Conditions

  • Carotid Stenosis

Interventions

DRUG

Fasudil Hydrochloride

Fasudil 40 mg three times a day x 14 days

DRUG

Placebo Oral Tablet

Placebo oral tablet manufactured to mimic fasudil three times a day x 14 days

Sponsors & Collaborators

  • Doris Duke Charitable Foundation

    collaborator OTHER

  • Brigham and Women's Hospital

    lead OTHER

Principal Investigators

  • Anju Nohria, MD · Brigham and Women's Hospital

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-03-13
Primary Completion
2011-01-20
Completion
2011-01-20

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00670202 on ClinicalTrials.gov